Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

REFILE-Novavax COVID-19 vaccine could be approved very soon, says EMA chief

12/07/2021 | 09:02am EST

BRUSSELS, Dec 7 (Reuters) - The head of the European Medicines Agency (EMA) on Tuesday said that it could soon approve the COVID-19 vaccine developed by U.S. biotech company Novavax.

"The vaccine from Novavax could be authorised in the very near future," Emer Cooke told EU health ministers during a public session of a meeting in Brussels. (Reporting by Francesco Guarascio Editing by David Goodman)


ę Reuters 2021
All news about NOVAVAX, INC.
01/25Germany to receive 3.8 mln doses of Novavax's new COVID vaccine in Q1
RE
01/21Cowen Starts Novavax at Outperform With $150 Price Target
MT
01/20Global markets live: Unilever, United Airlines, Amazon, Walt Disney, Novavax...
01/20WALL STREET STOCK EXCHANGE : Nasdaq aims for rebound after entering correction territory
01/20Health Care Stocks Advance Premarket Thursday
MT
01/20Bill & Melinda Gates Foundation and Wellcome Pledge U.S.$300 Million to CEPI for Covid-..
AQ
01/20Novavax Obtains Approval for Provisional Registration of COVID-19 Vaccine in Australia
MT
01/20Australia says no to 16-year-old forklift drivers as remedy to COVID supply chain pain
RE
01/19Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for No..
PR
01/19Valneva Shares Suffer as Coronavirus Vaccine Seen Arriving Too Late
DJ
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2021 1 365 M - -
Net income 2021 -938 M - -
Net cash 2021 756 M - -
P/E ratio 2021 -6,30x
Yield 2021 -
Capitalization 5 987 M 5 987 M -
EV / Sales 2021 3,83x
EV / Sales 2022 0,95x
Nbr of Employees 792
Free-Float -
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | NVAX | US6700024010 | MarketScreener
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 79,18 $
Average target price 250,00 $
Spread / Average Target 216%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-44.66%5 987
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
ICON PUBLIC LIMITED COMPANY-18.28%20 601